Suma Vupputuri, PhD, MPH, FAHA

Research Scientist


PhD, Tulane University School of Public Health and Tropical Medicine, 2001
MPH, Tulane University School of Public Health and Tropical Medicine, 1996

Suma Vupputuri is an epidemiologist with a focus on the etiology, prevention, and treatment of chronic disease. Her substantive areas of interest include heart disease, diabetes, and chronic kidney disease epidemiology, as well as health services and health disparities research. Dr. Vupputuri also worked at KP for over 4 years in the Georgia region and has experience with many types of studies including observational, pragmatic trials, and multi-site surveillance/data systems for studying trends in cardiovascular disease and diabetes.

Dr. Vupputuri has worked in a variety of different health research settings and has broad experience on how real-world health data is collected, managed, and processed in and across different systems. Her goal is to apply her research interests and experiences with “big data” to novel and exciting studies that will ultimately lead to better health outcomes for patients at KPMAS.

Dr. Vupputuri is an elected Fellow of the American Heart Association (FAHA) conferred by the Council on Epidemiology and Prevention and recognized for her excellence and sustained contributions to scholarship, practice, education, and volunteer service within in the American Heart Association. She has 10+ years of research experience; has published over 50 manuscripts in peer-reviewed journals; and served as PI/site-PI/co-PI on more than 15 funded studies.

Research Interests:

Chronic disease epidemiology (cardiovascular disease, diabetes, chronic kidney disease), health services, health disparities, comparative effectiveness, medication adherence, quality of care issues

For a full list of publications, please see Dr. Vupputuri’s Curriculum Vitae.

  1. Vupputuri S, Rubenstein KB, Derus AJ, Loftus B, Horberg MA. Factors Contributing to Racial Disparities in Influenza Vaccinations. American Journal of Managed Care, submitted.
  2. Reboussin DM, Allen N, Griswold ME, Guallar E, Hong Y, Lackland DT, Miller EPR, Polonsky T, Thompson-Paul AM, Vupputuri S. A Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA /PCNA Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Hypertension. 2017 Nov 13. [Epub ahead of print]
  3. Reynolds K, Adams KF, Boudreau D, Cassidy A, Fortmann SP, Go AS, Goldberg RJ, Greenlee R, Gunter M, Gurwitz JH, Lieu T, Magid DJ, McNeal CJ, Newton KM, Novotny R, Quesenberry CP, Smith DH, Steinhubl S, Tom JO, Vupputuri S, Waring SC, Sidney S. Trends in the Incidence of Hospitalized Acute Myocardial Infarction in the Cardiovascular Research Network (CVRN), 2000-2008. Am J Med. 2016 Oct 14. pii: S0002-9343(16)31020-8.
  4. Wu B, Bell K, Kern DM, Tunceli O, Willey V, Vupputuri S, Stanford A, Kalsekar I. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007-2012. BMJ Open Diabetes Res Care. 2016 Apr 11;4(1).
  5. Smith DH, O’Keefe-Rosetti M, Owen-Smith A, Rand C, Tom J, Vupputuri S, Laws R, Waterbury A, Hankerson-Dyson D, Yonehara C, Williams A, Shneider J, Dickerson JF, Vollmer WM. Improving Adherence to Cardiovascular Therapies: An Economic Evaluation of a Randomized Pragmatic Trial. Value Health. 2016 Mar;19(2):176-84. doi: 10.1016/j.jval.2015.11.013. Epub 2016 Feb 12.
  6. Vupputuri S, Joski JJ, Whooley M, Kilpatrick R, Robinson BE, Safford MM, Yun H, Muntner P. The Association of Statin Persistence and Uncontrolled Low Density Lipid Cholesterol Among Patients at High Risk of Coronary Heart Disease in a Managed Care Organization. Am J Manag Care. 2016 Mar 1;22(3):e106-15.
  7. Smith DH, Johnson ES, Adams K, Boudreau D, Cassidy A, Fortmann SP, Greenlee RT, Gunter M, Gurwitz JH, Lieu T, Magid DJ, McNeal CJ, Reynolds K, Steinhubl SR, Thorp M, Tom JO, Vupputuri S, VanWormer JJ, Weinstein J, Go AS, Sidney S. Comparative Effectiveness of Statin Therapy in Adults with Chronic Kidney Disease and Acute Myocardial Infarction. Am J Med. 2015 Jul 10.
  8. Vollmer W, Owen-Smith A, Tom J, Laws R, Ditmer D, Smith D, Waterbury A, Schneider J, Yonehara C, Williams A, Vupputuri S, Rand C. Health Information Technology Improves Adherence to Cardiovascular Medication and Lowers LDL Cholesterol: The PATIENT Randomized Clinical Trial. Am J Manag Care. 2014 Nov;20(11 Spec No. 17):SP502-10.
  9. Vupputuri S, Hajat C, Al-Houqani M, Osman O, Sreedharan J, Zhou S, Sherman SE, Weitzman M. Midwakh/Dokha Use in the Middle East and Globally: Still Much to Learn. Tob Control. 2016 Mar;25(2):236-41.
  10. Muntner P, Yun H, Sharma P, Delzell E, Kent S, Kilgore M, Farkouh ME, Vupputuri S, Bittner V, Rosenson RS, Levitan E, Safford MM. Prior low antihypertensive medication adherence is associated with an increased risk of low adherence and discontinuation of statin medications. Am J Cardiol. 2014 Sep 15;114(6):826-31.
  1. Cohort Study of Morbidity and Mortality in DSD Patients
    The goal of this proposal is to compare DSD Quality of Care Indicators (QCI) against actual DSD management delivered at large nationwide integrated HCSs. We will estimate the percentage of DSD patients who received care according to each QCI, compare incidence and prevalence of co-morbidities in DSD patients to the corresponding measures among frequency matched patients, and assess the proportion of prophylactic gonadectomies that show malignant or precursor lesions on the resulting pathology specimens.
    Site Primary Investigator
  2. Using Values Affirmation to Reduce the Effects of Perceived Discrimination on Hypertension Disparities
    The primary outcome is 6-month change in adherence to antihypertensive therapies with the secondary outcome of change in blood pressure. We will also explore possible mechanisms of the intervention effect and formally evaluate for dissemination.
    Co-Investigator/Site Primary Investigator
  3. Comparative Effectiveness of Timing and Type of Antiviral Treatment of Patients with HIV
    We will identify a cohort of HIV-infected patients and utilize high-dimensional propensity-matching to identify HIV-uninfected adults to assess the complex relationship between HIV and heart failure (HF). We will characterize the association of HIV status with the incidence of HF and HF type; investigate clinically meaningful treatment strategies for the prevention of HF and HF types in HIV-infected adults; and among new HF cases that develop among HIV-infected and HIV-uninfected adults, examine the association of HIV status on HF-related hospitalizations and death.
  4. Racial Disparities in Hypertension (RADISH): Decomposing the effects of risk factor distribution and risk factor impact on racial disparities
    The purpose of this study is to determine the extent to which the overall disparity in uncontrolled hypertension between
    Whites and Blacks can be explained by a comprehensive list of pre-specified covariates from KP databases; to calculate the percent contribution of each covariate to the total racial disparity in uncontrolled hypertension; and to calculate the percent contribution of the impact of each covariate to the total racial disparity in uncontrolled hypertension.
    Kaiser Permanente/Johns Hopkins Research Collaborative
    Primary Investigator
  5. Delayed Treatment Intensification and Risk of Diabetes Complications
    The purpose of this study is to assess the impact of delayed treatment intensification on diabetes complications among
    patients: 1) newly initiating metformin monotherapy; 2) adding a second oral agent; and 3) initiating insulin (after two or
    more oral agents).
    Sanofi Inc.
    Site Primary Investigator
  1. January 2015, Invited presentation: Kaiser Permanente Mid-Atlantic States, Mid-Atlantic Permanente Research Institute, Rockville, MD. “Big Data and Chronic Disease Research”.
  2. May 2013, Speaker/Host: Health Authority of Abu Dhabi, Department of Chronic Diseases, Abu Dhabi, UAE. “Asthma Guidelines Training Workshop” (Continuing Medical Education Workshop: 6.25 CME credits, 100 participants).
  3. April/May 2013, Speaker/Host: Health Authority of Abu Dhabi, Section of Cardiovascular and Metabolic Disorders, Abu Dhabi, UAE. “Training Workshop on the Weqaya Screening Programme” (Training of Weqaya facility clinicians and staff, 30 participants).
  4. March 2013, Guest speaker: Diabetes Complications Continuing Medical Education (CME) Workshop, Abu Dhabi, UAE. (Workshop sponsored by Pfizer).
  5. November 2012, Guest speaker: Health Authority of Abu Dhabi, Department of Cardiovascular and Metabolic Disorders, Abu Dhabi, UAE. “Training Workshop on the Weqaya Cardiovascular Screening Programme” (Training of Weqaya facilities).